GHRPs are oligopeptides with GH-releasing effects in humans when given by either parenteral or oral routes; in addition, nonpeptide pharmacologic analogues have recently been synthesized. Although the exact mechanism of action of these agents has not been fully established, there is probably a dual site of action on both the pituitary and the hypothalamus, possibly involving regulatory factors in addition to GHRH and somatostatin. GHRPs and their analogues may have a potential role in the treatment of short stature in children or in other situations of GH deficiency, such as adult GH deficiency, obesity, catabolic states, and even normal old age
International audienceGhrelin, the 28 amino acid peptide recently identified as the natural ligand f...
OBJECTIVE Both spontaneous and stimulated GH secretion are reduced in patients with hypothyroidism. ...
In insulin-dependent diabetes mellitus (IDDM), inappropriate growth hormone (GH) responses to severa...
GHRPs are oligopeptides with GH-releasing effects in humans when given by either parenteral or oral ...
The synthetic growth hormone-releasing peptides (GHRPs) and their nonpeptide analogues release growt...
The synthetic growth hormone-releasing peptides (GHRPs) and their nonpeptide analogues release growt...
Growth hormone-releasing peptides (GHRPs) are synthetic, non-natural peptides endowed with potent st...
The GH-releasing peptides (GHRPs) are a family of hexa- and heptapeptides that specifically stimulat...
Growth hormone-releasing hormone (GHRH) has been characterised as a 40-44 residue peptide with full ...
Summary Growth hormone-releasing peptides (GHRPs) are known to release growth hormone (GH) in vivo a...
Stimulation of pituitary GH secretion with administered GHRH can be effective therapy for those GH d...
Three analogues of growth hormone-releasing hormone (GHRH) have been compared in normal subjects. GH...
Altered GH responses to several pharmacological stimuli, including GHRH, have been found in hyperthy...
The hypothalamic neuropeptides growth hormone-releasing hormone (GHRH) and somatostatin (SS), respec...
Ghrelin, a 28 amino acid-acylated peptide predominantly produced by the stomach, displays strong gro...
International audienceGhrelin, the 28 amino acid peptide recently identified as the natural ligand f...
OBJECTIVE Both spontaneous and stimulated GH secretion are reduced in patients with hypothyroidism. ...
In insulin-dependent diabetes mellitus (IDDM), inappropriate growth hormone (GH) responses to severa...
GHRPs are oligopeptides with GH-releasing effects in humans when given by either parenteral or oral ...
The synthetic growth hormone-releasing peptides (GHRPs) and their nonpeptide analogues release growt...
The synthetic growth hormone-releasing peptides (GHRPs) and their nonpeptide analogues release growt...
Growth hormone-releasing peptides (GHRPs) are synthetic, non-natural peptides endowed with potent st...
The GH-releasing peptides (GHRPs) are a family of hexa- and heptapeptides that specifically stimulat...
Growth hormone-releasing hormone (GHRH) has been characterised as a 40-44 residue peptide with full ...
Summary Growth hormone-releasing peptides (GHRPs) are known to release growth hormone (GH) in vivo a...
Stimulation of pituitary GH secretion with administered GHRH can be effective therapy for those GH d...
Three analogues of growth hormone-releasing hormone (GHRH) have been compared in normal subjects. GH...
Altered GH responses to several pharmacological stimuli, including GHRH, have been found in hyperthy...
The hypothalamic neuropeptides growth hormone-releasing hormone (GHRH) and somatostatin (SS), respec...
Ghrelin, a 28 amino acid-acylated peptide predominantly produced by the stomach, displays strong gro...
International audienceGhrelin, the 28 amino acid peptide recently identified as the natural ligand f...
OBJECTIVE Both spontaneous and stimulated GH secretion are reduced in patients with hypothyroidism. ...
In insulin-dependent diabetes mellitus (IDDM), inappropriate growth hormone (GH) responses to severa...